Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study-Reference-Cited by-同舟云学术

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Published:2024-05 Issue: Volume: Page:
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Guo Wei,Wen Xuejun,Chen Yuhang,Zhao Tianzhi,Liu Jia,Tao Yucen^ORCID,Fu Hao,Wang Hongjian,Xu Weizhi^ORCID,Pang Yizhen^ORCID,Zhao Liang,Huang Jingxiong,Xu Pengfei,Guo Zhide,Miao Weibing,Zhang Jingjing,Chen Xiaoyuan^ORCID,Chen Haojun^ORCID

Publisher

Elsevier BV

Reference37 articles.

1. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy;Krenning;Ann Oncol,1999

2. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives;Appetecchia;J Exp Clin Cancer Res,2010

3. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017

4. The theranostic promise for neuroendocrine tumors in the late 2010s-where do we stand, where do we go?.;Werner;Theranostics,2018

5. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy;Liu;Chem Soc Rev,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-15